Leviticus Cardio successfully completes long-term animal study

Editor’s note: News of the Leviticus Cardio study appeared in Yahoo! Finance.

Leviticus Cardio confirms the successful completion of a long-term chronic animal study

Leviticus will participate in the ISHLT 2018 (International Society for Heart & Lung Transplantation) meeting. VAD update session, The Acropolis Congress Centre, Nice, France, 11-13 April 2018.

Leviticus Cardio CEO Michael Zilbershlag models the company’s wireless energy system for ventricular assist devices.

Leviticus Cardio, the inventor of wireless power transfer for Left Ventricular Assisted Devices (LVADs) for patients with severe cardiac issues, has announced another round of successful animal trials, well beyond periods required to demonstrate suitability for chronic conditions. The company confirms that the successful studies put it in a strong position to advance its long-term strategy.

LVADs are complex heart pumps for patients with significant cardiac muscle weakness. LVADs assist the patient’s heart for the duration of his life, and existing LVAD batteries require a powerline exiting the patient’s body (generally chest) for recharging.

Numerous experts have long viewed the driveline exiting a patient’s chest as the weak link in the LVAD architecture as it restricts patient lifestyle and is associated with high rates of infections, which can be lethal. Leviticus is the leader in wireless power transfer for LVADs, which would eliminate the driveline.

In the latest study, conducted at the Catholic University of Leuven, Belgium, under the supervision of Professor Bart Meyns, MD, PhD, the technology has demonstrated efficiency, safety, and stability with repeated cycles of eight hours of discharge and recharge of an internal battery-powered Mechanical Circulatory Support (MCS) device for more than 60 days.

Michael Zilbershlag, CEO of Leviticus Cardio, comments, “This is the first step of an ambitious strategy. Our goal is to offer versatile wireless energy transfer to all patients requiring long term MCS support. Many key international opinion leaders have already expressed their willingness to support us and demonstrate the possibility of our CET technology.”

Professor Stephan Schueler, MD, PhD, Newcastle upon Tyne, Freeman Hospital, UK, commented, “The successful completion of the animal trials with the wireless Coplanar Energy Transfer system opens a new era for long term LVAD implants.” Professor Jiri Maly, MD, PhD, from the Institute for Clinical and Experimental Medicine, Prague, stated that “based on our current experience, the CET system is easy to implant and doesn’t increase the complexity of surgery compared to a standard LVAD procedure.”

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize